After the establishment of the National Health Security Bureau, it will become the most concerned government department of drug companies. Why? There are three reasons:
1, market access
For the domestic pharmaceutical industry, what exactly is market access? We can narrowly understand: bidding, into the health insurance.
Pharmaceuticals through the bidding, is equal to the loss of the entire hospital market. Moreover, if the drugs do not enter the health insurance catalog, even through the bidding, there will be a very huge impact on its market.
Bidding, health insurance catalog are market access, and now these two rights are in the hands of the National Health Security Bureau, the importance of which is self-evident.
2, strict control of medication
Medicare fee control, obviously, is still the key word in 2018. In the health insurance cost control of the big move, for drug companies, into the catalog is just a threshold, hospital access and health insurance payment standards is the top priority.
The National Health Insurance Bureau has the right to control costs from the source, and will have direct control over drugs and auxiliary drugs that were previously used in large quantities. In addition, under the health insurance payment standard, it will prompt hospitals to use the lowest-cost drugs to treat patients on the basis of rational drug use. In the future, under the health insurance environment, the interests of all parties will be more obvious game.
3, directly determine the price of drugs
Previously, for the price of drugs, the NDRC tube pricing, the Ministry of Health Insurance tube health insurance catalog, the Health Commission tube bidding and purchasing, and finally paid for by the health insurance, spend money on can not talk about the price, can not manage to standardize the use of the results caused by the pressure of the health insurance is getting bigger and bigger.
Today, the National Health Protection Bureau to take over the bidding and procurement of drugs, on the one hand, reflecting the "who pays, who operates", on the other hand, in the reality of the health insurance funds, will be taken to the winning price of the drugs and health insurance payment standards closely tied to the way to achieve the interests of all parties to maximize.
In this case, hospitals or medical associations can negotiate drug prices based on health insurance payment standards. They can even commission third-party platforms and local health insurance bureaus to conduct drug negotiations. The ultimate goal is only one, to reduce drug prices and maximize benefits on the basis of health insurance payment standards.
It can be said that the health insurance will be from a number of perspectives, directly affecting the drug companies, and even related to the fate of the enterprise. And the helmsman of which is the National Health Protection Bureau.
"The Sanming model" will be promoted nationwide?
Gu Xin, a professor at Peking University's School of Government, told CyberLink that the newly established National Health Security Bureau, which integrates the management of the health insurance fund and the NDRC's power to manage the prices of medicines and healthcare services, will surely speed up the "three doctors' linkage", especially the reform of the healthcare insurance payment.
In fact, some provinces and cities have already taken the lead in completing the "three insurance" process. A typical example of this is the "Sanming model" in Fujian province, which has left a deep impression on people. The "Sanming model" has enabled the health insurance to play a key leveraging role in the "three medical linkage", ultimately realizing that the health insurance fund has turned from a loss to a profit, the procurement of medicines tends to be reasonable, and excessive medical treatment has been curbed.
In recent years, the state has repeatedly indicated in public that the new health care reform star "Sanming model" affirmation. From this point of view, after the establishment of the National Health Security Bureau, the national promotion of "Sanming model" is very likely.
Over the years, the centralized bidding and purchasing of medicines has been in a lot of chaos, and it is for this reason that during the many years of the National People's Congress and the Chinese People's Political Consultative Conference (CPPCC), many National People's Congress deputies and CPPCC members have called for the reform and improvement of the existing centralized bidding and purchasing of medicines and even called for the abolition of the policy.
For the centralized procurement of drugs for public hospitals, in this year's two sessions, a proposal bluntly stated that the drug bidding policy underwritten by the local government is seriously deviated from the alienation of administrative approval in disguise, giving rise to a series of problems, such as local protection, regional blockade, administrative monopoly, designated distribution of the winning bid, and even commercial bribery.
In the industry's call, bidding price reduction, secondary bargaining, hospital cost control, etc., are now urgent solution to the hot potato.
The current bidding control or abolition
National Health Protection Bureau of the emergence of the realization of the "three insurance". The new authority, which has both the power and the money, is expected to play an important role in determining the development of the health care system and the allocation of health resources, especially in the bidding and purchasing of drugs.
Professor Gu Xin said that the Chinese-style centralized bidding and procurement system for drugs is actually "only bidding, not purchasing", and therefore can only be called "centralized bidding for drugs". In the accelerated reform of health insurance payment, single-patient payment and DRG payment, in this case, for the drugs used in hospitals, centralized procurement of drugs is not necessary.
Professor Gu Xin believes that the current centralized purchasing of drugs will likely be abolished in about two to three years, if it is estimated that the current centralized purchasing of drugs will be abolished in the event of a smooth advancement of health insurance payment reform.
Pharmaceutical companies, a major reshuffle is coming
The unified management of "bidding, health insurance, drug prices," the three statutory health insurance bureau, is destined to play a huge role in the process of health care reform, which will completely affect all pharmaceutical companies, another major reshuffle will come.
Pharmaceutical bidding, health insurance directory, are the scope of market access, can not pass the bidding, can not enter the health insurance, will completely lose the national public hospital market.
At present, the domestic drug duplicative production of many, the competition is very fierce, but after all, the number of winning bids is limited, limited health insurance catalog, a large number of pharmaceutical enterprises lifeblood, seven inches will be firmly pinched, that is, it is possible to be completely eliminated. This will be a part of the drug companies will rise through the ranks, the pattern will be greatly changed.